TacticScaleWhat Medpace Does & How It Makes Money (MEDP)
Updated October 2026 · reflects Medpace's latest reported financials
Contract research organization running clinical trials for drug and device developers. Medpace earns service fees from drug, biotech and device sponsors that hire it to design, run and support their clinical trials.
How Medpace makes money
Medpace earns service fees from drug, biotech and device sponsors that hire it to design, run and support their clinical trials. It also charges for lab, imaging, ECG reading and regulatory services.
What Medpace does
Medpace Holdings is a contract research organization (CRO) that runs outsourced clinical development for the pharmaceutical, biotechnology and medical device industries. Its services cover the full clinical process from Phase I to Phase IV across many therapeutic areas. These include development plan design, project management, clinical monitoring, regulatory affairs, data management and analysis, pharmacovigilance, new drug application submissions and post-marketing support. Medpace also runs its own lab and specialty services: a coordinated central laboratory, bio-analytical labs, clinical human pharmacology, imaging and ECG reading. Founded in 1992 and based in Cincinnati, Ohio, it serves sponsors in North America, Europe, Asia, South America, Africa and Australia.
Products & services
- Phase I–IV clinical development services
- Central laboratory services
- Bio-analytical laboratory services
- Clinical human pharmacology
- Imaging and electrocardiography (ECG) reading services
- Regulatory affairs and pharmacovigilance support
What is Medpace worth?
On an owner-earnings DCF, Medpace's most-likely value is about $889 versus a recent price near $612 (45% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$244) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →